R9-13-201. Definitions

In this Article, unless otherwise specified:

1. "Abnormal result" means an outcome that deviates from the range of values established by:
   a. The Department for an analysis performed as part of a bloodspot test, or for a
      hearing test, or
   b. A health care facility or health care provider for critical congenital heart defect
      screening.

2. "Admission" or "admitted" means the same as in A.A.C. R9-10-101.


4. "Argininosuccinic acidemia" means a congenital disorder characterized by an inability to
   metabolize the amino acid argininosuccinic acid due to defective argininosuccinate lyase
   activity.

5. "Arizona State Laboratory" means the entity operated according to A.R.S. § 36-251.

6. "Audiological equipment" means an instrument used to help determine the presence,
   type, or degree of hearing loss by:
   a. Providing ear-specific and frequency-specific stimuli to an individual; or
   b. Measuring an individual’s physiological response to stimuli.

7. "Audiologist" means the same as in A.R.S. § 36-1901.

8. "Beta-ketothiolase deficiency" means a congenital disorder characterized by an inability
   to metabolize 2-methyl-acetoacetyl-CoA due to defective mitochondrial acetoacetyl-CoA
   thiolase activity.

9. "Biotinidase deficiency" means a congenital disorder characterized by defective
   biotinidase activity that causes abnormal biotin metabolism.

10. "Birth center" means a health care facility that is not a hospital and is organized for the
    sole purpose of delivering newborns.

11. "Blood sample" means capillary or venous blood, but not cord blood, applied to the filter
    paper of a specimen collection kit.
"Bloodspot test" means multiple laboratory analyses performed on a blood sample to screen for the presence of congenital disorders listed in R9-13-202 R9-13-203.

"Carnitine uptake defect" means a congenital disorder characterized by a decrease in the amount of free carnitine due to defective sodium ion-dependent carnitine transporter OCTN2 activity.

"Citrullinemia" means a congenital disorder characterized by an inability to convert the amino acid citrulline and aspartic acid into argininosuccinic acid due to defective argininosuccinate synthetase activity.

"Classic galactosemia" means a congenital disorder characterized by abnormal galactose metabolism due to defective galactose-1-phosphate uridylyltransferase activity.

"Congenital adrenal hyperplasia" means a congenital disorder characterized by decreased cortisol production and increased androgen production due to defective 21-hydroxylase activity.

"Congenital disorder" means an abnormal condition present at birth, as a result of heredity or environmental factors, that impairs normal physiological functioning of a human body.

"Congenital hypothyroidism" means a congenital disorder characterized by deficient thyroid hormone production.

“Critical congenital heart defect” means a heart abnormality or condition present at birth that places a newborn or infant at significant risk of disability or death if not diagnosed soon after birth.

"Cystic fibrosis" means a congenital disorder caused by defective functioning of a transmembrane regulator protein and characterized by damage to and dysfunction of various organs, such as the lungs, pancreas, and reproductive organs.

"Department" means the Arizona Department of Health Services.

“Diagnostic evaluation” means a hearing test performed by an audiologist or a physician to determine whether hearing loss exists, and, if applicable, determine the type or degree of hearing loss.

"Discharge" means the termination of inpatient services to a newborn or an infant.

"Disorder" means a disease or medical condition that may be identified by a laboratory analysis.

"Document" means to establish and maintain information in written, photographic, electronic, or other permanent form.
"Educational materials" means printed or electronic information provided by the Department, explaining newborn and infant screening, any of the congenital disorders listed in R9-13-202 R9-13-203, or hearing loss, or critical congenital heart defect.

"Electronic" means the same as in A.R.S. § 44-7002.

"First specimen" means the initial specimen that is collected from a newborn who is less than five days of age and sent to the Arizona State Laboratory for testing and recording of demographic information.

"Glutaric acidemia type I" means a congenital disorder characterized by an accumulation of glutaric acid due to defective glutaryl-CoA dehydrogenase activity.

"Guardian" means an individual appointed by a court under A.R.S. Title 14, Chapter 5, Article 2.

"Health care facility" means a health care institution defined in A.R.S. § 36-401 where obstetrical care or newborn care is provided.

"Health care provider" means a physician, physician assistant, registered nurse practitioner, or midwife.

"Health-related services" means the same as in A.R.S. § 36-401.

“Hearing screening” means a hearing test to determine the likelihood of hearing loss in a newborn or infant.

"Hearing test" means an evaluation of each of a newborn’s or an infant’s ears, using audiological equipment to:

a. Screen the newborn or infant for a possible hearing loss;
b. Determine that the newborn or infant does not have a hearing loss; or
c. Diagnose a hearing loss in the newborn or infant, including, if applicable, determining the type or degree of hearing loss.

"Hemoglobin S/Beta-thalassemia" means a sickle cell disease in which an individual has one sickle cell gene and one gene for beta thalassemia, another inherited hemoglobinopathy.

"Hemoglobin S/C disease" means a sickle cell disease in which an individual has one sickle cell gene and one gene for another inherited hemoglobinopathy called hemoglobin C.

"Hemoglobinopathy" means a congenital disorder characterized by abnormal production, structure, or functioning of hemoglobin.

"Home birth" means delivery of a newborn, outside a health care facility, when the newborn is not hospitalized within 72 hours of delivery.
"Homocystinuria" means a congenital disorder characterized by abnormal methionine and homocysteine metabolism due to defective cystathione-ß-synthase activity.

"Hospital" means the same as in A.A.C. R9-10-101.

"Hospital services" means the same as in A.A.C. R9-10-201.

"3-Hydroxy-3-methylglutaric aciduria" means a congenital disorder characterized by the accumulation of 3-hydroxy-3-methylglutaric acid due to a defective 3-hydroxy-3-methylglutaryl-CoA lyase activity.

"Identification code" means a unique set of numbers or letters, or a unique set of both numbers and letters, assigned by the Department to a health care facility, a health care provider, an audiologist, or another person submitting specimen collection kits to the Arizona State Laboratory or hearing test results to the Department.

"Infant" means the same as in A.R.S. § 36-694.

"Inpatient" means an individual who:
   a. Is admitted to a hospital,
   b. Receives hospital services for 24 consecutive hours, or
   c. Is admitted to a birth center.

"Inpatient services" means medical services, nursing services, or other health-related services provided to an inpatient in a health care facility.

"Isovaleric acidemia" means a congenital disorder characterized by an accumulation of isovaleric acid due to defective isovaleryl-CoA dehydrogenase activity.

"Long-chain 3-hydroxy acyl-CoA dehydrogenase deficiency" means a congenital disorder characterized by an inability to metabolize fatty acids that are 12 to 16 carbon atoms in length due to defective long-chain 3-hydroxy acyl-CoA dehydrogenase activity.

"Maple syrup urine disease" means a congenital disorder of branched chain amino acid metabolism due to defective branched chain-keto acid dehydrogenase activity.

"Medical services" means the same as in A.R.S. § 36-401.

"Medium chain acyl-CoA dehydrogenase deficiency" means a congenital disorder characterized by an inability to metabolize fatty acids that are 6 to 10 carbon atoms in length due to defective medium-chain acyl-CoA dehydrogenase activity.

"3-Methylcrotonyl-CoA carboxylase deficiency" means a congenital disorder characterized by an accumulation of 3-methylcrotonyl-glycine due to defective 3-methylcrotonyl-CoA carboxylase activity.
§4-54. "Methylmalonic acidemia (Cbl A,B)" means a congenital disorder characterized by an accumulation of methylmalonic acid due to defective activity of methylmalonyl-CoA racemase or adenosylcobalamin synthetase.

§2-55. "Methylmalonic acidemia (mutase deficiency)" means a congenital disorder characterized by an accumulation of methylmalonic acid due to defective methylmalonyl-CoA mutase activity.

§3-56. "Midwife" means an individual licensed under A.R.S. Title 36, Chapter 6, Article 7, or certified under A.R.S. Title 32, Chapter 15.

§4-57. "Multiple carboxylase deficiency" means a congenital disorder characterized by an inability to transport or metabolize biotin that leads to defective activity of propionyl-CoA carboxylase, beta-methylcrotonyl-CoA carboxylase, and pyruvate carboxylase.

§5-58. "Newborn" means the same as in A.R.S. § 36-694.

§6-59. "Newborn care" means medical services, nursing services, and health-related services provided to a newborn.

§7-60. "Nursing services" means the same as in A.R.S. § 36-401.

§8-61. "Obstetrical care" means medical services, nursing services, and health-related services provided to a woman throughout her pregnancy, labor, delivery, and postpartum.

§9-62. "Organ" means a somewhat independent part of a human body, such as a salivary gland, kidney, or pancreas, which performs a specific function.

§10-63. "Parent" means a natural, adoptive, or custodial mother or father of a newborn or an infant.

§11-64. "Parenteral nutrition" means the feeding of an individual intravenously through the administration of a formula containing glucose, amino acids, lipids, vitamins, and minerals.

§12-65. "Person" means the state, a municipality, district, or other political subdivision, a cooperative, institution, corporation, company, firm, partnership, individual, or other legal entity.

§13-66. "Phenylketonuria" means a congenital disorder characterized by abnormal phenylalanine metabolism due to defective phenylalanine hydroxylase activity.

§14-67. "Physician" means an individual licensed under A.R.S. Title 32, Chapters 13, 14, 17, or 29.

§15-68. "Physician assistant" means an individual licensed under A.R.S. Title 32, Chapter 25.
"Propionic acidemia" means a congenital disorder characterized by an accumulation of glycine and 3-hydroxypropionic acid due to defective propionyl-CoA carboxylase activity.

“Pulse oximetry” means a non-invasive method of measuring the percentage of hemoglobin in the blood that is saturated with oxygen using a device approved by the U.S. Food and Drug Administration for use with newborns or infants less than six weeks of age.

"Registered nurse practitioner" means the same as in A.R.S. § 32-1601.

"Second specimen" means a specimen that is sent to the Arizona State Laboratory for testing and recording of demographic information, after being collected:

a. From a newborn after a first specimen; or

b. From an individual at least five days and not older than one year of age, regardless of whether a first specimen was collected.

“Severe combined immunodeficiency” means a congenital disorder usually characterized by a defect in both the T- and B-lymphocyte systems, which typically results in the onset of one or more serious infections within the first few months of life.

"Sickle cell anemia" means a sickle cell disease in which an individual has two sickle cell genes.

"Sickle cell disease" means a hemoglobinopathy characterized by an abnormally shaped red blood cell resulting from the abnormal structure of the protein hemoglobin.

"Sickle cell gene" means a unit of inheritance that is involved in producing an abnormal type of the protein hemoglobin, in which the amino acid valine is substituted for the amino acid glutamic acid at a specific location in the hemoglobin.

"Specimen" means a blood sample obtained from and demographic information about a newborn or an infant.

"Specimen collection kit" means a strip of filter paper for collecting a blood sample attached to a form for obtaining the information specified in R9-13-203(A)(3) R9-13-203(C)(3) about a newborn or an infant.

"Transfer" means a health care facility or health care provider discharging a newborn and sending the newborn to a hospital for inpatient medical services without the intent that the patient will be returned to the sending health care facility or health care provider.

"Transfusion" means the infusion of blood or blood products into the body of an individual.
"Trifunctional protein deficiency" means a congenital disorder characterized by an inability to metabolize fatty acids that are 12 to 18 carbon atoms in length due to defective mitochondrial trifunctional protein activity.

"Tyrosinemia type I" means a congenital disorder characterized by an accumulation of the amino acid tyrosine due to defective fumarylacetoacetate hydrolase activity.

"Verify" means to confirm by obtaining information through a source such as the newborn screening program, a health care provider, a health care facility, or a documented record.

"Very long-chain acyl-CoA dehydrogenase deficiency" means a congenital disorder characterized by an inability to metabolize fatty acids that are 14 to 18 carbon atoms in length due to defective very long-chain acyl-CoA dehydrogenase activity.

"Working day" means 8:00 a.m. through 5:00 p.m. Monday through Friday, excluding state holidays.


A bloodspot test shall screen for the following congenital disorders:

1. 3-Hydroxy-3-methylglutaric aciduria,
2. 3-Methylcrotonyl-CoA carboxylase deficiency,
3. Argininosuccinic acidemia,
4. Beta-ketothiolase deficiency,
5. Biotinidase deficiency,
6. Carnitine uptake defect,
7. Citrullinemia,
8. Classic galactosemia,
9. Congenital adrenal hyperplasia,
10. Congenital hypothyroidism,
11. Cystic fibrosis,
12. Glutaric acidemia type I,
13. Hemoglobin S/Beta-thalassemia,
14. Hemoglobin S/C disease,
15. Homocystinuria,
16. Isovaleric acidemia,
17. Long-chain 3-hydroxy acyl-CoA dehydrogenase deficiency,
18. Maple syrup urine disease,
19. Medium chain acyl-CoA dehydrogenase deficiency,
20. Methylmalonic acidemia (Cbl A,B),
21. Methylmalonic acidemia (mutase deficiency),
22. Multiple carboxylase deficiency,
23. Phenylketonuria,
24. Propionic acidemia,
25. Sickle cell anemia,
26. Trifunctional protein deficiency,
27. Tyrosinemia type I, and

A. A health care facility’s designee, a health care provider, or a health care provider’s designee shall order critical congenital heart defect screening using pulse oximetry for a newborn to be performed:
   1. Between 24 and 48 hours after birth according to the health care facility’s or health care provider’s policies and procedures, or
   2. As late as possible before discharge according to the health care facility’s or health care provider’s policies and procedures if the newborn is discharged earlier than 24 hours after birth.

B. Before critical congenital heart defect screening is performed on a newborn, a health care facility’s designee, a health care provider, or a health care provider’s designee shall provide educational materials to the newborn’s parent or guardian.

C. When critical congenital heart defect screening is ordered for a newborn, a health care facility’s designee, a health care provider, or a health care provider’s designee shall submit, in a format specified by the Department, the following information:
   1. The newborn’s name, gender, race, ethnicity, medical record number, and, if applicable, AHCCCS identification number;
   2. Whether the newborn is from a single or multiple birth;
   3. If the newborn is from a multiple birth, the birth order of the newborn;
   4. The date and time of birth, and the newborn's weight at birth;
   5. The identification code or the name and address of the health care facility or health care provider submitting the information;
   6. Except as provided in subsection (C)(7), the mother's first and last names, date of birth, name before first marriage, mailing address, telephone number, and, if applicable, AHCCCS identification number;
7. If the newborn's mother does not have physical custody of the newborn, the first and last names, mailing address, and telephone number of the person who has physical custody of the newborn;

8. The date, time, and result of the critical congenital heart defect screening;

9. If critical congenital heart defect screening was not performed, the reason critical congenital heart defect screening was not performed;

10. If the newborn was transferred to another health care facility or health care provider before the critical congenital heart defect screening was performed, the name, address, and telephone number of the health care facility or health care provider to which the newborn was transferred; and

11. Whether the newborn has a medical condition that may affect the critical congenital heart defect screening results.

D. In addition to the information in subsection (C), if the reported result of critical congenital heart defect screening for a newborn or infant is abnormal, a health care facility’s designee, a health care provider, or a health care provider’s designee shall submit to the Department, upon request and in a format specified by the Department, the following information:

1. The dates, times, values of all critical congenital heart defect screening results;

2. The dates, times, and results of any subsequent tests performed as a result of critical congenital heart defect screening;

3. The name, address, and telephone number of the contact person for the health care facility, health care provider, or other person performing the subsequent tests; and

4. If a medical condition is found as a result of critical congenital heart defect screening or subsequent tests, the type of medical condition found and the name of the health care provider who will be responsible for the coordination of medical services for the newborn or infant after the newborn or infant is discharged.

R9-13-203. General Requirements for Newborn and Infant Bloodspot Tests

A. A bloodspot test shall screen for the following congenital disorders:

1. 3-Hydroxy-3-methylglutaric aciduria,

2. 3-Methylcrotonyl-CoA carboxylase deficiency,

3. Argininosuccinic acidemia,

4. Beta-ketothiolase deficiency,

5. Biotinidase deficiency,

6. Carnitine uptake defect,

7. Citrullinemia,
8. Classic galactosemia,
9. Congenital adrenal hyperplasia,
10. Congenital hypothyroidism,
11. Cystic fibrosis,
12. Glutaric acidemia type I,
13. Hemoglobin S/Beta-thalassemia,
14. Hemoglobin S/C disease,
15. Homocystinuria,
16. Isovaleric acidemia,
17. Long-chain 3-hydroxy acyl-CoA dehydrogenase deficiency,
18. Maple syrup urine disease,
19. Medium chain acyl-CoA dehydrogenase deficiency,
20. Methylmalonic acidemia (Cbl A,B),
21. Methylmalonic acidemia (mutase deficiency),
22. Multiple carboxylase deficiency,
23. Phenylketonuria,
24. Propionic acidemia,
25. Sickle cell anemia,
26. Trifunctional protein deficiency,
27. Tyrosinemia type I, and

B. In addition to the congenital disorders listed in subsection (A), a bloodspot test may screen for severe combined immunodeficiency when sufficient funding is available to the Department to cover the cost of the Department’s activities related to the screening for severe combined immunodeficiency.

A-C. When a bloodspot test is ordered for a newborn or an infant, a health care facility's designee, a health care provider, or the health care provider's designee shall:

1. Only use a specimen collection kit supplied by the Department;
2. Collect a blood sample from the newborn or infant on a specimen collection kit;
3. Complete the following information on the specimen collection kit:
   a. The newborn's or infant's name, gender, race, ethnicity, medical record number, and, if applicable, AHCCCS identification number;
   b. The newborn's or infant's type of food or food source;
   c. Whether the newborn or infant is from a single or multiple birth;
d. If the newborn or infant is from a multiple birth, the birth order of the newborn or infant;

e. Whether the newborn or infant has a medical condition that may affect the bloodspot test results;

f. Whether the newborn or infant received a blood transfusion and, if applicable, the date of the last blood transfusion;

g. The date and time of birth, and the newborn's or infant's weight at birth;

h. The date and time of blood sample collection, and the newborn's or infant's weight when the blood sample is collected;

i. The identification code or the name and address of the health care facility or health care provider submitting the specimen collection kit;

j. The name, address, and telephone number or the identification code of the health care provider responsible for the management of medical services provided to the newborn or infant;

k. Except as provided in subsection (A)(3)(l) (C)(3)(1), the mother's first and last names, date of birth, name before first marriage, mailing address, telephone number, and if applicable, AHCCCS identification number; and

l. If the newborn's or infant's mother does not have physical custody of the newborn or infant, the first and last names, mailing address, and telephone number of the person who has physical custody of the newborn or infant; and

4. Submit the specimen collection kit to the Arizona State Laboratory no later than 24 hours or the next working day after the blood sample is collected.

B.D. A health care facility or a health care provider submitting a first specimen to the Arizona State Laboratory shall pay the Department the fee in R9-13-208(A).

C.E. A person who submits a second specimen to the Arizona State Laboratory shall:

1. Pay the fee in R9-13-208(B) to the Department, or

2. Provide the following information to the Arizona State Laboratory for billing purposes:

   a. The name, mailing address, and telephone number of the newborn's or infant's parent or the individual responsible for paying, if not the parent; and

   b. If the individual responsible for paying has health care insurance for the newborn or infant, information about the health care insurance, including:

      i. The policyholder's name;

      ii. The name and billing address of the health care insurance company;

      iii. The member identification number;
iv. The group number, if applicable; and
v. The effective date of the health care insurance; or

c. That the individual responsible for paying has no health care insurance for the
newborn or infant.

D-F. When a health care insurance company or an individual responsible for paying is identified as
specified in subsection (C)(2) (E)(2), the health care insurance company or the individual
responsible for paying shall pay the Department the fee in R9-13-208(B).

E-G. When a home birth not attended by a health care provider is reported to a local registrar, a deputy
local registrar, or the state registrar under A.R.S. § 36-333:
1. The local registrar, deputy local registrar, or state registrar shall notify the local health
department of the county where the birth occurred; and
2. The local health department's designee shall collect a specimen from the newborn or
infant according to the requirements in R9-13-204(A)(2) or R9-13-205(C).

F-H. A health care facility's designee, a health care provider, or the health care provider's designee
shall ensure that:
1. Educational materials are provided to the parent or guardian of a newborn or an infant for
whom a bloodspot test is ordered, and
2. The newborn's or infant's parent or guardian is informed of the requirement for a second
specimen if the second specimen has not been collected.

G-I. For a home birth, a health care provider or the health care provider's designee shall provide
educational materials to the parent or guardian of a newborn or an infant for whom a bloodspot
test is ordered.

R9-13-207. Reporting Requirements for Hearing Test Results Newborn and Infant Hearing
Tests
A. Before a hearing test is performed on a newborn or infant, a health care facility’s designee, a
health care provider, or the health care provider’s designee shall provide educational materials to
the newborn’s or infant’s parent or guardian.

B. A health care facility’s designee, a health care provider, or the health care provider’s designee
shall order hearing testing for a newborn or infant to be performed according to the health care
facility’s or health care provider’s policies and procedures that includes:
1. An initial hearing screening ordered to be performed within 30 days after birth or before
discharge;
2. A second hearing screening ordered to be performed within 30 days after birth if an
abnormal result is obtained in one or both of a newborn’s or infant’s ears on the initial
hearing screening; and
3. Diagnostic evaluation ordered to be performed:
   a. If a newborn or infant has an abnormal result in one or both ears on the second hearing screening;
   b. If a newborn or infant has been admitted to the Neonatal Intensive Care Unit for five days or more and has an abnormal initial hearing screening;
   c. If a newborn or infant has a medical condition that makes diagnostic evaluation more appropriate; or
   d. As clinically indicated.

A-C. When an initial hearing test is performed on a newborn or infant, a health care facility's designee, a health care provider, or the health care provider's designee shall provide the Department, as specified in subsection (E) (G), the following information:
   1. The newborn's or infant's name, date of birth, gender, and medical record number;
   2. Whether the newborn or infant is from a single or multiple birth;
   3. If the newborn or infant is from a multiple birth, the birth order of the newborn or infant;
   4. The first and last names and date of birth of the newborn's or infant's mother;
   5. The name and identification code of the health care facility of birth;
   6. If the initial hearing test was not performed by the health care facility of birth, either:
      a. The name and identification code of the health care facility where the initial hearing test was performed, or of the health care provider who performed the initial hearing test;
      b. The name and telephone number of the health care provider who performed the initial hearing test;
   7. The name of the health care provider responsible for the coordination of medical services for the newborn;
   8. The date of the initial hearing test;
   9. Whether or not the initial hearing test was performed when the newborn or infant was an inpatient;
   10. The audiological equipment used for the initial hearing test and the type of initial hearing test performed; and
   11. The initial hearing test result for each of the newborn's or infant's ears; and
   12. The name, address, and telephone number of the contact person for the health care facility or health care provider.

B-D. In addition to the information in subsection (A) (C), if the reported results of an initial hearing test on a newborn or infant include an abnormal result, a health care facility's designee, a health care provider, or the health care provider's designee shall provide the Department, as specified in subsection (E) (G), the following information:

13
care provider, or the health care provider's designee shall provide submit to the Department, as specified in subsection (E)(G), the following information:

1. The newborn's race, ethnicity, and if applicable, AHCCCS identification number;
2. Except as provided in subsection (D)(3), the mother's name before first marriage, mailing address, and telephone number;
3. If the newborn's or infant’s mother does not have physical custody of the newborn or infant, the first and last names, mailing address, and telephone number of the person who has physical custody of the newborn or infant;
4. The name of the health care provider who will be responsible for the coordination of medical services for the newborn or infant after the newborn or infant is discharged from the health care facility, if different from the health care provider specified in subsection (A)(7); and
5. The name and telephone number of the person to whom the newborn's or infant’s mother or other person who has physical custody of the newborn or infant was referred for a subsequent hearing test;
6. The date of the appointment for a subsequent hearing test, if available; and
7. The health care facility where a subsequent hearing test is scheduled to be performed or the name and address of the health care provider who is scheduled to perform the subsequent test, if available.

C.E. When a subsequent hearing test is performed on a newborn or an infant after an initial hearing test, the designee of the health care facility, health care provider, or other person that performs the subsequent hearing test shall provide submit to the Department, as specified in subsection (E)(G), the following information:

1. The newborn's or infant's name, date of birth, and gender;
2. Whether the newborn or infant is from a single or multiple birth;
3. If the newborn or infant is from a multiple birth, the birth order of the newborn or infant;
4. The first and last names and date of birth of the newborn’s or infant’s mother;
5. The name of the health care facility of birth, if known;
6. If the initial hearing test was not performed by the health care facility of birth, either:
   a. The name of the health care facility where the initial hearing test was performed, or
   b. The name and telephone number of the health care provider who performed the initial hearing test;
6. The name of the health care facility where the subsequent hearing test was performed, or
the name and address of the health care provider who performed the subsequent hearing test;
7. The name, telephone number, and identification code of the person submitting the subsequent hearing test results;
8-7. The date of the subsequent hearing test;
9-8. The audiological equipment used for the subsequent hearing test and type of hearing test performed;
10. The type of hearing test performed;
11. The result, including a quantitative result if applicable, for each of the newborn’s or infant’s ears on the subsequent hearing test;
12. The name, address and telephone number of the contact person for the health care facility, health care provider, or other person that performed the subsequent hearing test, if different from the person specified in subsection (E)(6); and
12-11. If the subsequent hearing test was performed by an audiologist or a physician to determine that the newborn or infant does not have a hearing loss or diagnose a hearing loss in the newborn or infant a diagnostic evaluation:
   a. Whether the newborn or infant has a hearing loss and, if so, the type and degree of hearing loss; and
   b. A copy of the narrative that describes the hearing test performed on the newborn or infant to determine that the newborn or infant does not have a hearing loss or diagnose a hearing loss in the newborn or infant, the results of the hearing test, and the analysis of the hearing test results by the audiologist or physician who performed the hearing test; and
   c. Whether the newborn or infant has a medical condition that may affect the hearing test results.
13. The name, address, and telephone number of the contact person for the health care facility, health care provider, or other person that performed the subsequent hearing test, if different from the person specified in subsection (C)(7).
D.F. In addition to the information in subsection (C) (E), if the reported results of a subsequent hearing test on a newborn or infant include an abnormal result, the person submitting the report on the subsequent hearing test shall provide submit to the Department, as specified in subsection (E) (G), the following information:
1. Except as provided in subsection (D)(2) (F)(2), the mailing address and telephone number of the newborn’s or infant’s mother;
2. If the newborn's or infant's mother does not have physical custody of the newborn or infant, the first and last names, mailing address, and telephone number of the person who has physical custody of the newborn or infant;
3. The name of the health care provider who is responsible for the coordination of medical services for the newborn or infant; and
4. If applicable, the name and phone telephone number of the person to whom the newborn's or infant's parent was referred for further hearing tests, evaluation services, specialty care, or early intervention.

E-G. A health care facility's designee, health care provider, health care provider's designee, or other person required to report under subsections (A), (B), (C), or (D) (C), (D), (E), or (F) shall submit, in an electronic format specified by the Department, the information specified in subsections (A), (B), (C), or (D) (C), (D), (E), or (F) for hearing tests performed each week by the sixth day of the subsequent week.

R9-13-208. Fees
A. The fee for a first specimen is $30.00.
B. The fee for a second specimen is $65.00.